# Noveltreat Patient Profile Matcher > Match an adult obese patient to the best-fit evidence anchor for Noveltreat (semaglutide 2.4 mg) using the 7 Sun Pharma monograph obesity profiles — medically-supervised weight loss, obese + uncontrolled T2DM, obese + CVD / HFpEF risk, obese + knee osteoarthritis, obese + MASH, obese + prediabetes, and obese + PCOS. Use when a clinician describes a candidate for semaglutide 2.4 mg and wants the matching STEP / SELECT / STEP-HFpEF / ESSENCE / STEP 9 / STEP 10 trial with key numbers, clinical concerns, and the "why Noveltreat" rationale. Grounded in Sun Pharmaceutical Industries Ltd. Product Monograph — Diabetes and Obesity (2026). - Skill: `dromlakhani/noveltreat-patient-profile-matcher` (Agent Skill) - Install (CLI): `npx skillmds@latest add dromlakhani/noveltreat-patient-profile-matcher` - Raw SKILL.md: https://api.skillmd.com/api/skills/dromlakhani/noveltreat-patient-profile-matcher/raw - Safety review: pending (external: skill-scanner PASS, skillspector PASS) - Works with: Claude Code, Claude.ai, OpenAI Codex - Category: Coding & Dev Tools - Author: dromlakhani (https://skillmd.com/u/dromlakhani) - Updated: 2026-09-08 - Page: https://skillmd.com/skills/dromlakhani/noveltreat-patient-profile-matcher --- # Noveltreat — Patient Profile Matcher (Obesity, semaglutide 2.4 mg) ## How to Use 1. Read the patient's description (age, sex, BMI, HbA1c, comorbidities, current therapy). 2. Match to **one of the 7 profiles** below — pick the profile whose dominant feature matches. 3. Return: anchor trial + key numbers + clinical concerns + why Noveltreat fits. 4. If the patient fits > 1 profile, list each in priority order and name the primary driver. --- ## Profile 1 — Obese patient seeking medically-supervised weight loss - **Typical patient:** BMI ≥ 30 (or ≥ 27 + comorbidity), no T2DM, failed diet/exercise alone, no prior anti-obesity pharmacotherapy. - **Concerns:** weight beyond what diet/exercise achieves; sustained weight + waist reduction; safe long-term pharmacotherapy. - **Anchor trials:** STEP 1, 3, 4, 5. - **Key numbers:** - Weight: **−14.9 to −17.4 %** at 68 weeks (STEP 4) - **69.1 %** ≥ 10 % loss; **50.5 %** ≥ 15 % loss - Waist circumference: **−14.6 cm** - STEP 5 (104 weeks): sustained **−15.2 %**, 77.1 % with ≥ 5 % loss - STEP 4 withdrawal: continued semaglutide −7.9 % vs placebo +6.9 % - **Why Noveltreat:** central appetite suppression, durable loss to 2 years, improved cardiometabolic risk, simple once-weekly dosing. --- ## Profile 2 — Obese patient with uncontrolled T2DM - **Typical patient:** BMI ~ 31, HbA1c ~ 7.8 %, on metformin ± SGLT2, persistent hyperglycemia and weight issues. - **Concerns:** glycemic gap, weight persistence, long-term cardiometabolic risk, adherence. - **Anchor trial:** STEP 2. - **Key numbers:** - Weight: **−9.6 %** (vs −3.4 % placebo; p < 0.0001) - HbA1c: **−1.6 %** (from 8.1 %) - **68.8 %** achieved ≥ 5 % weight loss - **Why Noveltreat:** meaningful HbA1c reduction alongside weight loss; RSSDI / ADA endorse GLP-1 RA escalation when HbA1c 7–9 % on dual/dual+ with persistent weight issues; high compliance. --- ## Profile 3 — Obese patient with established CVD and/or HFpEF risk - **Typical patient:** BMI ~ 33, prior MI, high HFpEF risk, dyslipidemia/HTN/prediabetes. - **Concerns:** recurrent CV risk, HFpEF progression, functional capacity, disease-modifying therapy. - **Anchor trials:** SELECT, STEP-HFpEF (obesity + T2DM), STEP-HFpEF (no DM), STEP 5. - **Key numbers:** - **MACE ↓ 20 %** over 39 months vs placebo (SELECT) - Weight: **−8.51 %**; CRP **−43.5 %** - 6-minute walk distance: **+21.5 m** - KCCQ-CSS: **+16.6** points (vs +8.7 placebo); 32.3 % achieved ≥ 15-point improvement at week 52 - STEP 5: 77.1 % ≥ 5 % weight loss at week 104 - **Why Noveltreat:** CV benefit independent of T2DM; improved HFpEF symptoms, physical function, QoL; addresses weight + inflammation + CV risk simultaneously; aligned with ACC 2025 / ESC guidelines. --- ## Profile 4 — Obese patient with knee osteoarthritis - **Typical patient:** BMI ~ 34, chronic knee pain, limited mobility, unable to exercise adequately. - **Concerns:** meaningful weight loss despite exercise limitation, reduction in pain and functional impairment, long-term adherence. - **Anchor trial:** STEP 9. - **Key numbers:** - Weight: **−13.7 %** (vs −3.2 % placebo) at 68 weeks - WOMAC pain score: **−41.7** points (vs −27.5 placebo); > 50 % achieved ≥ 41.2-point improvement - SF-36 physical function: **+12** points (vs +6.5 placebo) - **Why Noveltreat:** substantial weight loss reduces mechanical knee stress; improves physical function and mobility scores; enables gradual re-engagement in activity; once-weekly simplicity. --- ## Profile 5 — Obese patient with MASH (metabolic dysfunction-associated steatohepatitis) - **Typical patient:** BMI ~ 31, F2 fibrosis, prediabetes (HbA1c ~ 6.4 %), metabolic syndrome, on metformin ± pioglitazone. - **Concerns:** halting fibrosis, steatohepatitis resolution, safe option in multi-morbid patient. - **Anchor trial:** ESSENCE (interim analysis at week 72). - **Key numbers:** - Fibrosis reduction: **36.8 %** (vs 22.4 % placebo) - MASH resolution without fibrosis worsening: **62.9 %** (vs 34.3 %); absolute difference 28.7 %, p < 0.001 - Combined steatohepatitis resolution + fibrosis reduction: **32.7 %** (vs 16.1 %); absolute difference 14.4 %, p < 0.001 - Weight: **−10.5 %** - **Why Noveltreat:** currently the only FDA-approved glucose-lowering / obesity medication for MASH; improves insulin resistance, liver inflammation, cardiometabolic markers; low hypoglycemia risk. --- ## Profile 6 — Obese patient with prediabetes - **Typical patient:** BMI ~ 32, HbA1c ~ 6.1 %, FPG ~ 110 mg/dL, Class I obesity, mild dyslipidemia/HTN. - **Concerns:** effective weight loss beyond lifestyle, prevention-focused intervention, adherence. - **Anchor trial:** STEP 10. - **Key numbers:** - **81 %** reversion to normoglycemia (vs 14 % placebo) - Weight: **−13.9 %** (vs −2.7 % placebo) - **Why Noveltreat:** produces substantial sustained weight loss > 10 %; improves insulin sensitivity; facilitates reversion from prediabetes to normoglycemia. --- ## Profile 7 — Obese patient with PCOS - **Typical patient:** BMI ~ 33, irregular / oligomenorrhoeic cycles, insulin-resistant, ≥ 6 months of structured lifestyle with inadequate response, on metformin. - **Concerns:** sustained weight loss, insulin resistance, menstrual regularity, hyperandrogenism, fertility goals. - **Anchor trials:** STEP 1, STEP 5, and obesity-PCOS study (semaglutide 0.5 mg SC, 3 months). - **Key numbers:** - PCOS study: mean weight −7.6 kg, BMI −3.1 kg/m², −8.9 % body weight at 3 months - **80 %** of patients on 0.5 mg semaglutide had regular menstrual cycles - STEP 1: 32 % achieved ≥ 20 % weight loss at 68 weeks - STEP 5: 36.1 % ≥ 20 % loss at 104 weeks; fasting insulin **−32.7 %** vs −7.2 % placebo - **Why Noveltreat:** meaningful sustained weight loss is central to improving PCOS pathophysiology; helps maintain loss long-term; improves waist circumference, metabolic and inflammatory markers. --- ## Output Template When returning a match, use this structure: ``` Best-fit profile: . Anchor trial(s): Expected outcomes: Why Noveltreat fits: <3–5 bullet rationale> Caveats: → Dose and start: see `noveltreat-prescribing-guide` ``` If the patient has T2DM + CKD instead of obesity focus, note that Noveltreat is the **obesity brand** — Sematrinity is the T2DM brand; recommend checking the companion T2DM profile sheet. ## Reference Sun Pharmaceutical Industries Ltd. **Product Monograph — Diabetes and Obesity (Sematrinity® and Noveltreat®)**, 2026 (Data on file).